SEATTLE--(BUSINESS WIRE)--Nov. 7, 2016--
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed
to discovering, developing and commercializing both small-molecule and
protein therapeutics for large-market as well as orphan indications
targeting inflammation, coagulopathies and disorders of the central
nervous system, today announced that the company will issue its third
quarter 2016 financial results for the period ended September 30, 2016,
on Wednesday, November 9, 2016, after the market closes. Omeros
management will host a conference call and webcast that day at 4:30 p.m.
Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results.
Conference Call Details
To access the live conference call via phone, please dial 844-831-4029
from the United States and Canada or 920-663-6278 internationally. The
participant passcode is 15159376. Please dial in approximately 10
minutes prior to the start of the call. A telephone replay will be
available for one week following the call and may be accessed by dialing
855-859-2056 from the United States and Canada or 404-537-3406
internationally. The replay passcode is 15159376.
To access the live and subsequently archived webcast of the conference
call, go to Omeros’ website at www.omeros.com
and go to “Events” under the Investors section of the website. Please
connect to the website at least 15 minutes prior to the call to allow
for any software download that may be necessary.
About Omeros Corporation
Omeros is a biopharmaceutical company committed to discovering,
developing and commercializing both small-molecule and protein
therapeutics for large-market as well as orphan indications targeting
inflammation, coagulopathies and disorders of the central nervous
system. Part of its proprietary PharmacoSurgery® platform,
the company’s first drug product, OMIDRIA® (phenylephrine and
ketorolac injection) 1%/0.3%, was broadly launched in the U.S. in April
2015. OMIDRIA is the first and only FDA-approved drug (1) for use during
cataract surgery or intraocular lens (IOL) replacement to maintain pupil
size by preventing intraoperative miosis (pupil constriction) and to
reduce postoperative ocular pain and (2) that contains an NSAID for
intraocular use. In the European Union, the European Commission has
approved OMIDRIA for use in cataract surgery and lens replacement
procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil
constriction), and to reduce postoperative eye pain. Omeros has
clinical-stage development programs focused on: complement-associated
thrombotic microangiopathies; complement-mediated
glomerulonephropathies; Huntington’s disease and cognitive impairment;
and addictive and compulsive disorders. In addition, Omeros has a
proprietary G protein-coupled receptor (GPCR) platform, which is making
available an unprecedented number of new GPCR drug targets and
corresponding compounds to the pharmaceutical industry for drug
development, and a platform used to generate antibodies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161107005482/en/
Source: Omeros Corporation
Cook Williams Communications, Inc.
Investor and Media Relations
Jennifer
Cook Williams, 360-668-3701
